Bicara Therapeutics Inc
NASDAQ:BCAX
Intrinsic Value
The intrinsic value of one BCAX stock under the Base Case scenario is 8.98 USD. Compared to the current market price of 11.11 USD, Bicara Therapeutics Inc is Overvalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Bicara Therapeutics Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Bicara Therapeutics Inc
Balance Sheet Decomposition
Bicara Therapeutics Inc
Current Assets | 470.8m |
Cash & Short-Term Investments | 462.1m |
Other Current Assets | 8.7m |
Non-Current Assets | 7.3m |
PP&E | 688k |
Other Non-Current Assets | 6.6m |
Free Cash Flow Analysis
Bicara Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Bicara Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-124.2m
USD
|
Operating Income
|
-124.2m
USD
|
Other Expenses
|
19.3m
USD
|
Net Income
|
-104.8m
USD
|
BCAX Profitability Score
Profitability Due Diligence
Bicara Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Bicara Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
BCAX Solvency Score
Solvency Due Diligence
Bicara Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Bicara Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCAX Price Targets Summary
Bicara Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BCAX is 33.25 USD with a low forecast of 8.08 USD and a high forecast of 50.4 USD.
Dividends
Current shareholder yield for BCAX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one BCAX stock under the Base Case scenario is 8.98 USD.
Compared to the current market price of 11.11 USD, Bicara Therapeutics Inc is Overvalued by 19%.